Brief: Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For Lp-184 In Advanced Solid Tumors
25/09/2023 13:36
Sept 25 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN THE PHASE
1
STUDY FOR LP-184 IN ADVANCED SOLID TUMORS
* LANTERN PHARMA INC- ANTICIPATES PHASE 1A PORTION OF TRIAL
TO BE
COMPLETED IN FIRST HALF OF 2024
Source text for Eikon: ID:nBw9Sc933a
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview